Because of an alteration of the tertiary structure of BCR-ABL1, the TKI response mechanism is different, but CML patients show a very good response to therapy and have a good prognosis (Duan et al. 2017). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.